<?xml version='1.0' encoding='utf-8'?>
<document id="25297720"><sentence text="Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications."><entity charOffset="11-23" id="DDI-PubMed.25297720.s1.e0" text="lumefantrine" /></sentence><sentence text="Drug-drug interactions between antimalarial and antiretroviral drugs may influence antimalarial treatment outcomes" /><sentence text=" The aim of this study was to investigate the potential drug-drug interactions between the antimalarial drugs, lumefantrine, artemether and their respective metabolites desbutyl-lumefantrine and dihydroartemisinin, and the HIV drugs efavirenz, nevirapine and lopinavir/ritonavir"><entity charOffset="111-123" id="DDI-PubMed.25297720.s3.e0" text="lumefantrine" /><entity charOffset="125-135" id="DDI-PubMed.25297720.s3.e1" text="artemether" /><entity charOffset="169-190" id="DDI-PubMed.25297720.s3.e2" text="desbutyl-lumefantrine" /><entity charOffset="195-213" id="DDI-PubMed.25297720.s3.e3" text="dihydroartemisinin" /><entity charOffset="233-242" id="DDI-PubMed.25297720.s3.e4" text="efavirenz" /><entity charOffset="244-254" id="DDI-PubMed.25297720.s3.e5" text="nevirapine" /><entity charOffset="259-268" id="DDI-PubMed.25297720.s3.e6" text="lopinavir" /><entity charOffset="269-278" id="DDI-PubMed.25297720.s3.e7" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e0" e2="DDI-PubMed.25297720.s3.e7" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e1" e2="DDI-PubMed.25297720.s3.e7" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e2" e2="DDI-PubMed.25297720.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e2" e2="DDI-PubMed.25297720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e2" e2="DDI-PubMed.25297720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e2" e2="DDI-PubMed.25297720.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e2" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e2" e2="DDI-PubMed.25297720.s3.e7" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e3" e2="DDI-PubMed.25297720.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e3" e2="DDI-PubMed.25297720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e3" e2="DDI-PubMed.25297720.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e3" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e3" e2="DDI-PubMed.25297720.s3.e7" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e4" e2="DDI-PubMed.25297720.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e4" e2="DDI-PubMed.25297720.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e4" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e4" e2="DDI-PubMed.25297720.s3.e7" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e5" e2="DDI-PubMed.25297720.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e5" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e5" e2="DDI-PubMed.25297720.s3.e7" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e6" e2="DDI-PubMed.25297720.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25297720.s3.e6" e2="DDI-PubMed.25297720.s3.e7" /></sentence><sentence text="" /><sentence text="Data from two clinical studies, investigating the influence of the HIV drugs efavirenz, nevirapine and lopinavir/ritonavir on the pharmacokinetics of the antimalarial drugs lumefantrine, artemether and their respective metabolites, in HIV infected patients were pooled and analyzed using a non-linear mixed effects modelling approach"><entity charOffset="77-86" id="DDI-PubMed.25297720.s5.e0" text="efavirenz" /><entity charOffset="88-98" id="DDI-PubMed.25297720.s5.e1" text="nevirapine" /><entity charOffset="103-112" id="DDI-PubMed.25297720.s5.e2" text="lopinavir" /><entity charOffset="113-122" id="DDI-PubMed.25297720.s5.e3" text="ritonavir" /><entity charOffset="173-185" id="DDI-PubMed.25297720.s5.e4" text="lumefantrine" /><entity charOffset="187-197" id="DDI-PubMed.25297720.s5.e5" text="artemether" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e0" e2="DDI-PubMed.25297720.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e0" e2="DDI-PubMed.25297720.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e0" e2="DDI-PubMed.25297720.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e0" e2="DDI-PubMed.25297720.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e0" e2="DDI-PubMed.25297720.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e0" e2="DDI-PubMed.25297720.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e1" e2="DDI-PubMed.25297720.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e1" e2="DDI-PubMed.25297720.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e1" e2="DDI-PubMed.25297720.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e1" e2="DDI-PubMed.25297720.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e1" e2="DDI-PubMed.25297720.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e2" e2="DDI-PubMed.25297720.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e2" e2="DDI-PubMed.25297720.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e2" e2="DDI-PubMed.25297720.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e2" e2="DDI-PubMed.25297720.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e3" e2="DDI-PubMed.25297720.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e3" e2="DDI-PubMed.25297720.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e3" e2="DDI-PubMed.25297720.s5.e5" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e4" e2="DDI-PubMed.25297720.s5.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s5.e4" e2="DDI-PubMed.25297720.s5.e5" /></sentence><sentence text="" /><sentence text="Efavirenz and nevirapine significantly decreased the terminal exposure to lumefantrine (decrease of 69"><entity charOffset="0-9" id="DDI-PubMed.25297720.s7.e0" text="Efavirenz" /><entity charOffset="14-24" id="DDI-PubMed.25297720.s7.e1" text="nevirapine" /><entity charOffset="74-86" id="DDI-PubMed.25297720.s7.e2" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.25297720.s7.e0" e2="DDI-PubMed.25297720.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s7.e0" e2="DDI-PubMed.25297720.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s7.e0" e2="DDI-PubMed.25297720.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s7.e1" e2="DDI-PubMed.25297720.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s7.e1" e2="DDI-PubMed.25297720.s7.e2" /></sentence><sentence text="9% and 25" /><sentence text="2%, respectively) while lopinavir/ritonavir substantially increased the exposure (increase of 439%)"><entity charOffset="24-33" id="DDI-PubMed.25297720.s9.e0" text="lopinavir" /><entity charOffset="34-43" id="DDI-PubMed.25297720.s9.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25297720.s9.e0" e2="DDI-PubMed.25297720.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s9.e0" e2="DDI-PubMed.25297720.s9.e1" /></sentence><sentence text=" All antiretroviral drugs decreased the total exposure to dihydroartemisinin (decrease of 71"><entity charOffset="58-76" id="DDI-PubMed.25297720.s10.e0" text="dihydroartemisinin" /></sentence><sentence text="7%, 41" /><sentence text="3% and 59" /><sentence text="7% for efavirenz, nevirapine and ritonavir/lopinavir, respectively)"><entity charOffset="7-16" id="DDI-PubMed.25297720.s13.e0" text="efavirenz" /><entity charOffset="18-28" id="DDI-PubMed.25297720.s13.e1" text="nevirapine" /><entity charOffset="33-42" id="DDI-PubMed.25297720.s13.e2" text="ritonavir" /><entity charOffset="43-52" id="DDI-PubMed.25297720.s13.e3" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e0" e2="DDI-PubMed.25297720.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e0" e2="DDI-PubMed.25297720.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e0" e2="DDI-PubMed.25297720.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e0" e2="DDI-PubMed.25297720.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e1" e2="DDI-PubMed.25297720.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e1" e2="DDI-PubMed.25297720.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e1" e2="DDI-PubMed.25297720.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e2" e2="DDI-PubMed.25297720.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s13.e2" e2="DDI-PubMed.25297720.s13.e3" /></sentence><sentence text=" Simulations suggest that a substantially increased artemether-lumefantrine dose is required to achieve equivalent exposures when co-administered with efavirenz (250% increase) and nevirapine (75% increase)"><entity charOffset="63-75" id="DDI-PubMed.25297720.s14.e0" text="lumefantrine" /><entity charOffset="151-160" id="DDI-PubMed.25297720.s14.e1" text="efavirenz" /><entity charOffset="181-191" id="DDI-PubMed.25297720.s14.e2" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.25297720.s14.e0" e2="DDI-PubMed.25297720.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s14.e0" e2="DDI-PubMed.25297720.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s14.e0" e2="DDI-PubMed.25297720.s14.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s14.e1" e2="DDI-PubMed.25297720.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s14.e1" e2="DDI-PubMed.25297720.s14.e2" /></sentence><sentence text=" When co-administered with lopinavir/ritonavir it is unclear if the increased lumefantrine exposure compensates adequately for the reduced dihydroartemisinin exposure and thus whether dose adjustment is required"><entity charOffset="27-36" id="DDI-PubMed.25297720.s15.e0" text="lopinavir" /><entity charOffset="37-46" id="DDI-PubMed.25297720.s15.e1" text="ritonavir" /><entity charOffset="78-90" id="DDI-PubMed.25297720.s15.e2" text="lumefantrine" /><entity charOffset="139-157" id="DDI-PubMed.25297720.s15.e3" text="dihydroartemisinin" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e0" e2="DDI-PubMed.25297720.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e0" e2="DDI-PubMed.25297720.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e0" e2="DDI-PubMed.25297720.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e0" e2="DDI-PubMed.25297720.s15.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e1" e2="DDI-PubMed.25297720.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e1" e2="DDI-PubMed.25297720.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e1" e2="DDI-PubMed.25297720.s15.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e2" e2="DDI-PubMed.25297720.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s15.e2" e2="DDI-PubMed.25297720.s15.e3" /></sentence><sentence text="" /><sentence text="There are substantial drug interactions between artemether-lumefantrine and efavirenz, nevirapine and ritonavir/lopinavir"><entity charOffset="59-71" id="DDI-PubMed.25297720.s17.e0" text="lumefantrine" /><entity charOffset="76-85" id="DDI-PubMed.25297720.s17.e1" text="efavirenz" /><entity charOffset="87-97" id="DDI-PubMed.25297720.s17.e2" text="nevirapine" /><entity charOffset="102-111" id="DDI-PubMed.25297720.s17.e3" text="ritonavir" /><entity charOffset="112-121" id="DDI-PubMed.25297720.s17.e4" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e0" e2="DDI-PubMed.25297720.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e0" e2="DDI-PubMed.25297720.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e0" e2="DDI-PubMed.25297720.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e0" e2="DDI-PubMed.25297720.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e0" e2="DDI-PubMed.25297720.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e1" e2="DDI-PubMed.25297720.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e1" e2="DDI-PubMed.25297720.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e1" e2="DDI-PubMed.25297720.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e1" e2="DDI-PubMed.25297720.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e2" e2="DDI-PubMed.25297720.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e2" e2="DDI-PubMed.25297720.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e2" e2="DDI-PubMed.25297720.s17.e4" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e3" e2="DDI-PubMed.25297720.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25297720.s17.e3" e2="DDI-PubMed.25297720.s17.e4" /></sentence><sentence text=" Given the readily saturable absorption of lumefantrine, the dose adjustments predicted to be necessary will need to be evaluated prospectively in malaria-HIV co-infected patients"><entity charOffset="43-55" id="DDI-PubMed.25297720.s18.e0" text="lumefantrine" /></sentence><sentence text="" /></document>